Skip to main content

Illinois IGB

lasso peptides

Lassogen raises $4.5M in seed round to develop novel therapeutics

November 2, 2020

Although small molecule drugs and antibodies continue to be the standard for cancer treatment, a new class of therapeutics — lasso peptides — may prove effective, especially for disease targets that thwart traditional approaches. Combining the power of antibodies and small molecule drugs, the San Diego-based startup Lassogen is developing lasso peptides as a new therapeutic modality. Now, with $4.5 million raised in a seed round, the company moves one step closer to demonstrating the power of lasso peptides for treating human diseases such as cancer and autoimmune disorders. 

November 2, 2020

Related Articles

Subscribe to lasso peptides